Cyclerion Therapeutics, INC 10-Q quarterly reports

Cyclerion Therapeutics' Q2 2026 10-Q filing reveals substantial doubt about its ability to continue as a going concern, alongside details of a proposed merger with Korsana Biosciences.

Cyclerion Therapeutics reports Q1 2026 results, highlighting a significant net loss and ongoing preparations for a merger with Korsana Biosciences, while facing substantial going concern doubts.

Cyclerion Therapeutics reports reduced net losses and increased revenue, secures a new license for treatment-resistant depression, but faces substantial doubt about its ability to continue as a going concern.

Cyclerion Therapeutics reports a reduced net loss and improved operating cash flow for Q2 2025, driven by an insurance recovery and new financing, but faces substantial doubt about its ability to continue as a going concern.

Cyclerion Therapeutics reports a net loss of $1.429 million for the first quarter of 2025 and discusses its strategic focus on neuropsychiatric diseases, particularly treatment-resistant depression (TRD).

Cyclerion Therapeutics' Q3 2024 results show a net loss, but include revenue from a new option agreement and reduced operating expenses.

Cyclerion Therapeutics reported its second quarter 2024 financial results, highlighting a net loss and ongoing concerns about its ability to continue as a going concern.

Cyclerion Therapeutics reported a net loss of $1.54 million for the first quarter of 2024, as it continues to shift its strategy towards identifying new central nervous system assets.